Photodynamic therapy using ultradeformable liposomes loaded with chlorine aluminum phthalocyanine against L. (V.) braziliensis experimental models

Escobar, Patricia; Vera, Angélica María; Neira, Laura Fernanda; Velásquez, Alex O.; Carreño, Heider

doi:10.1016/j.exppara.2018.09.016

Cited by 24 publications

(14 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, an explorative study using topical NE-ClAlPc+15%PM/15 days plus or without PDT was unable to reduce CL lesions on L. (V.) braziliensis infected mice. Similar results were obtained with ClAlPc associated to liposomes in BALB/c mice infected with L. braziliensis [ 11 ]. It is possible that the poor ClAlPc permeation through the skin limited the efficacy of the PDT in vivo .…”

Section: Discussionsupporting

confidence: 85%

“…The highest activity of NE-ClAlPc-15%PM was expressed against intracellular amastigotes after PDT. The antileishmanial activities of ClAlPc (free or encapsulated or combined with others molecules such as uroporphyrin) against different mammalian cells and Leishmania species has been previously demonstrated [ 10 11 29 ].…”

Section: Discussionmentioning

confidence: 99%

“…Exogenous photosensitizers such as phenothiazine, porphyrins and phthalocyanine (Pc) or endogenous photosensitizers such as δ-aminolevulinic acid (ALA)-induced protoporphyrin IX have given interesting results in CL models [ 5 7 8 9 ]. Aluminium-phthalocyanine chloride (ClAlPc) is a chemically stable and commercially available photosensitizer active against different Leishmania species after PDT [ 9 10 11 ]. The poor solubility of unsubstituted metal-phthalocyanines and their high molecular weight (574.96 g.mol -1 for ClAlPc), however, are some of the major concerns regarding its topical use [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

“…The poor solubility of unsubstituted metal-phthalocyanines and their high molecular weight (574.96 g.mol -1 for ClAlPc), however, are some of the major concerns regarding its topical use [ 12 ]. Thus, ClAlPc has been encapsulated in different nanocarriers, such as liposomes, polymeric nanoparticles and nanoemulsions (NEs), and tested against different eukaryotic cells, including Leishmania , showing higher activity in terms of parasite inhibition [ 10 11 13 14 ].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Nanoemulsions with Chloroaluminium Phthalocyanine and Paromomycin for Combined Photodynamic and Antibiotic Therapy for Cutaneous Leishmaniasis

et al. 2021

View full text Add to dashboard Cite

Background Photodynamic therapy (PDT) using chloroaluminium phthalocyanine (ClAlPc) and paromomycin sulfate (PM) can be effective against New World Leishmania species involved in cutaneous leishmaniasis (CL). The aim of this study is to assay the skin permeation and the antileishmanial effects of a nanoemulsion (NE) containing both ClAlPc and PM in experimental CL by Leishmania (Viannia) braziliensis . Material and Methods Cremophor ELP/castor oil-based NEs were prepared by a low-energy method and characterized for their physicochemical parameters. The NEs were used to deliver both ClAlPc and PM to leishmania cells. The in vitro toxicity of NEs were tested in vitro against L. (V.) braziliensis and THP-1 cells. The in vivo toxicity was assessed in non-infected BALB/c mice. Ex-vivo permeation and retention studies using healthy mice skin were also conducted. Finally, the in vivo activity of NE-PM+ClAlPc after PDT was tested in BALB/c mice infected with parasites. Results NEs are colloidally stable with average droplet diameter of 30 nm, polydispersity index (PDI) below 0.2, and zeta potential near zero. Both promastigotes and intracellular amastigotes treated with NE-PM, NE-ClAlPc and NE-PM+ClAlPc were inhibited at >50%, >95%, >88%, respectively, after PDT with a phototoxic index (PI) >1.2. No skin ClAlPc permeation was observed. In contrast, PM skin permeation was 80-fold higher using PM-loaded NE formulation in comparison to aqueous PM solution. Topical treatment with NE formulations showed no signs of local toxicity or genotoxicity. In addition, concentrations of PM between 27.3 - 292.5 μM/25 mg of tissue were detected in different organs. In vivo , the NE-PM+ClAlPc treatment did not reduce skin lesions. Conclusion The Cremophor ELP/castor oil NE formulation increases the permeation of PM through the skin and can be used to co-deliver PM plus ClAlPc for combined PDT protocols. However, the lack of efficacy in the in vivo model evidences that the therapeutical scheme has to be improved.

show abstract

Section: Discussionsupporting

confidence: 85%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Nanoemulsions with Chloroaluminium Phthalocyanine and Paromomycin for Combined Photodynamic and Antibiotic Therapy for Cutaneous Leishmaniasis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Similarly, the use of ultra-deformable liposomes with sodium cholate improved skin-drug delivery of AICIPC during PDT. It exhibited anti-leishmanial properties against L.braziliensis by exerting excellent penetration potential in the dermis, ROS generation, DNA damaging effects however, limited selectivity of the formulation limited its healing ability during CL [144]. Thus, this field remains an exciting venture for future research to develop an inexpensive, non-toxic therapeutic approach.…”

Section: Photodynamic Therapy (Pdt)mentioning

confidence: 99%

Exploiting knowledge on pharmacodynamics-pharmacokinetics for accelerated anti-leishmanial drug discovery/development

Sundar

Agrawal

Singh

2019

Expert Opinion on Drug Metabolism & Toxicology

View full text Add to dashboard Cite

Introduction-Being on the top list of neglected tropical diseases, leishmaniasis has been marked for elimination by 2020. In the light of small armamentarium of drugs and their associated drawbacks, the understanding of pharmacodynamics and/or pharmacokinetics becomes priority to achieve disease elimination and sustaining it.Areas covered-We have looked into pharmacological aspects of existing and emerging drugs for treatment of leishmaniasis. An in depth understanding of pharmacodynamics and pharmacokinetics (PKPD) provides rational for drug designing and optimizing the treatment strategies. It forms a key to prevent the drug resistance and avoid drug associated adverse effects. We have compiled the researches on understanding the PKPD of different anti-leishmanial formulations, that holds hopes for improved and/or effective disease intervention.Expert opinion-Understanding the pharmacological aspect of drug forms the basis for the clinical application of novel drugs. Tailoring drugs dosage and individualized treatment can avoid the adverse events and bridge gap between the in vitro models and their clinical application. An integrated approach, with pragmatic use of technological advances can improve phenotypic screening, physiochemical properties of novel drugs. Concomitantly, this can serve to improve clinical efficacies, reduce incidence of relapse and accelerate the drug discovery/development process for leishmaniasis elimination.

show abstract

Leishmaniasis

Imani¹,

Dehghan²

2020

Nanobiotechnology in Diagnosis, Drug Delivery, and Treatment

View full text Add to dashboard Cite

Photodynamic therapy using ultradeformable liposomes loaded with chlorine aluminum phthalocyanine against L. (V.) braziliensis experimental models

Cited by 24 publications

References 38 publications

Nanoemulsions with Chloroaluminium Phthalocyanine and Paromomycin for Combined Photodynamic and Antibiotic Therapy for Cutaneous Leishmaniasis

Nanoemulsions with Chloroaluminium Phthalocyanine and Paromomycin for Combined Photodynamic and Antibiotic Therapy for Cutaneous Leishmaniasis

Exploiting knowledge on pharmacodynamics-pharmacokinetics for accelerated anti-leishmanial drug discovery/development

Leishmaniasis

Contact Info

Product

Resources

About